Cardiovascular and Metabolic Outcomes of Hormone Replacement Therapy in Women Aged 65 Years and Older: A Systematic Review of Randomized Clinical Trials
Taraneh Mousavi, Md Fitrat Hossain, Fadia T Shaya, Wanda Hill, Stephen N Davis · 2026
Read Cardiovascular and Metabolic Outcomes of Hormone Replacement Therapy in Women Aged 65 Years and Older: A Systematic Review of Randomized Clinical Trials by Taraneh Mousavi, Md Fitrat Hossain, Fadia T Shaya, Wanda Hill, Stephen N Davis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571631.txt.
Description
Taraneh Mousavi and co-authors review trial evidence on hormone therapy in women who start it at sixty five or older. Their 2026 review covers heart, kidney, and metabolic outcomes. Such effects in late starters are poorly mapped, the authors note. Four databases were searched for trials from 2021 to early 2026. Only six reports qualified, all drawn from three parent trials.
In the largest trial's analyses, estrogen alone or with a progestin lowered bad cholesterol. Both regimens raised triglycerides and systolic blood pressure, though. Estrogen plus progestin had a worse coronary profile than estrogen alone. A second trial spoke to vessel health by timing of treatment. Bias risk was rated with a standard tool where it applied. Findings were combined in narrative form. The authors stress that effects vary by regimen and by when therapy starts.
Catalog record
| CREATOR | Taraneh Mousavi, Md Fitrat Hossain, Fadia T Shaya, Wanda Hill, Stephen N Davis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |